New York, May 22, 2026, 06:06 (EDT)
Tyra Biosciences shares were last quoted at $33.02 before Friday’s regular Nasdaq session, keeping the clinical-stage biotech below its 52-week high as investors weighed a fresh rare-cancer awareness push against a year still driven by trial data. The stock’s 52-week range was $8.75 to $40.65, with market value near $2 billion.
Friday is not a U.S. stock-market holiday. Nasdaq’s calendar lists Memorial Day, Monday, May 25, as closed, leaving TYRA set for a normal regular session unless company-specific news or broader biotech flows shift the tape.
The latest Tyra item was not an efficacy update. Tyra and the Bladder Cancer Advocacy Network said they had established May 21 as Upper Tract Urothelial Cancer Awareness Day, a move aimed at raising attention around a rare cancer that affects the lining of the kidneys and ureters. BCAN Chief Executive Meri-Margaret Deoudes said UTUC “has historically received limited attention,” while Tyra Chief Executive Todd Harris said oral dabogratinib could offer a “kidney-sparing treatment approach.” Tyra Biosciences, Inc.
That matters now because dabogratinib sits at the center of Tyra’s valuation. FGFR3, short for fibroblast growth factor receptor 3, is a gene pathway tied to some urothelial cancers and skeletal-growth disorders; Tyra is trying to block it more selectively than older FGFR drugs.
The company’s May 13 filing showed three Phase 2 studies under way or planned around dabogratinib: SURF303 in low-grade UTUC, SURF302 in intermediate-risk non-muscle invasive bladder cancer, and BEACH301 in children with achondroplasia, a genetic condition that affects bone growth. Tyra said it expects initial three-month complete-response data from SURF302 in August, BEACH301 safety and growth data in the fourth quarter, and initial SURF303 results in 2027; complete response means no detectable signs of cancer at the assessment point.
Cash is the other part of the story. The company had $383.5 million in cash, cash equivalents and marketable securities at March 31, while its first-quarter net loss widened to $39.3 million from $28.1 million a year earlier. Tyra said that cash should fund operations into the second half of 2028, but added it has never generated revenue.
Wall Street has not treated the name like a quiet small-cap biotech. Wolfe Research this week initiated Tyra with a Peerperform rating, saying the UTUC program could be first to market and estimating $300 million to $400 million in U.S. unadjusted peak sales for that indication, according to Investing.com. The firm also said August bladder-cancer data will be a key test of the drug’s response profile.
There is competition, and not just in one lane. UroGen Pharma already has gel-based bladder-cancer products in the market, including Zusduri, which Reuters reported won FDA approval last year for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer after a trial showed a 78% complete response.
In achondroplasia, BridgeBio has put pressure on the field with oral infigratinib. Reuters reported in February that the drug improved growth rate by 1.74 cm versus placebo after 52 weeks and that BridgeBio plans to seek U.S. and European approval in the second half of 2026; BioMarin’s injectable Voxzogo is the approved incumbent.
The risk is simple and large. Tyra’s stock is trading on the promise that dabogratinib can deliver clean enough efficacy and safety across several diseases, but early or interim trial results can change as more patients are followed. The company also said it could spend cash faster than expected, and may need equity, debt or partners if development takes longer or regulators require more work.
For now, the May 21 awareness campaign keeps the rare-cancer story visible. The next hard stock test is data, not messaging.
